Last close As at 05/08/2026
SEK6.71
▲ −0.16 (−2.33%)
Market capitalisation
SEK435m
Research: Healthcare
Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myeloid leukaemia (AML), with recent endorsements from both the FDA and EMA (on the design of the planned registrational trial). Separately, Mendus has decided to cease further development for its second asset, ilixadencel, after the termination of its collaboration agreement with Institut Bergonié, sponsor of the REGOMUNE trial. We note that the termination was due to this basket study being prematurely halted, and not specifically related to ilixadencel. We view Mendus’s new streamlined approach to its lead programme as logical, especially given the promising long-term survival data from the ADVANCE II trial. For ilixadencel, management plans to explore other strategic options, of which a partnering agreement may be a priority, in our view. As we adjust our estimates to reflect the new approach for ilixadencel’s development plan, our valuation shifts slightly to SEK39.0/share (SEK40.3/share previously).
Mendus |
Regulatory endorsement supports vididencel focus |
Valuation update |
Pharma and biotech |
3 January 2025 |
Share price performance
Business description
Next events
Analysts
Mendus is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myeloid leukaemia (AML), with recent endorsements from both the FDA and EMA (on the design of the planned registrational trial). Separately, Mendus has decided to cease further development for its second asset, ilixadencel, after the termination of its collaboration agreement with Institut Bergonié, sponsor of the REGOMUNE trial. We note that the termination was due to this basket study being prematurely halted, and not specifically related to ilixadencel. We view Mendus’s new streamlined approach to its lead programme as logical, especially given the promising long-term survival data from the ADVANCE II trial. For ilixadencel, management plans to explore other strategic options, of which a partnering agreement may be a priority, in our view. As we adjust our estimates to reflect the new approach for ilixadencel’s development plan, our valuation shifts slightly to SEK39.0/share (SEK40.3/share previously).
Year |
Revenue (SEKm) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/22 |
3.4 |
(138.8) |
(13.9) |
0.0 |
N/A |
N/A |
12/23 |
29.6 |
(101.6) |
(4.4) |
0.0 |
N/A |
N/A |
12/24e |
5.2 |
(135.8) |
(2.8) |
0.0 |
N/A |
N/A |
12/25e |
0.0 |
(122.1) |
(2.4) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. EPS adjusted for 20:1 share consolidation (June 2024).
Regulatory green light for vididencel Phase III trial
Mendus started 2025 on an encouraging note, with positive feedback following the end-of-Phase 2 meeting with the FDA and the EMA on its trial design (including patient population, control arm and primary and secondary endpoints) and strategy for the planned pivotal trial. The Phase III programme will evaluate vididencel in combination with oral azacitidine as a maintenance treatment in AML. Following the updated long-term survival data from ADVANCE II, as well as confirmation that the large-scale manufacturing of vididencel through the alliance with NorthX Biologics is on track, this feedback is another endorsement of vididencel’s potential in AML, in our view, and we believe it supports Mendus’s decision to focus exclusively on its lead programme. For a more detailed discussion, please see our recent outlook note.
Ilixadencel on hold – strategy adjustment
Given that Mendus’s core focus is vididencel in AML, ilixadencel was being explored more opportunistically in the earlier stages of clinical development. Therefore, we are not surprised by the company’s decision to cease further development following the news that Institut Bergonié, sponsor of REGOMUNE, has halted its collaboration. Ilixadencel has previously shown encouraging data in solid tumours, and we believe the programme now represents an opportunity for Mendus to seek partnerships to support further development efforts.
Valuation: SEK1.96bn or SEK39.0 per share
We still see potential in ilixadencel, but tweak our estimates to reflect higher risk. Our valuation adjusts to SEK1.96bn or SEK39.0/share (SEK2.03bn or SEK40.3/share previously); ilixadencel now accounts for 9% of our valuation (16.6% previously).
Research: Industrials
The aerospace sector outlook remains positive, with lengthy order books at the primes (Airbus and Boeing) and total passenger flying hours in 2024 on schedule to exceed post-pandemic levels, supporting a strong aftermarket. The former will assist margin recovery for Melrose Industries’ original equipment (OE) operations, while increased flying hours are already generating strong growth and margin in the aftermarket business. Hence, our adjustment to estimates for external factors, such as FX movements, should not detract investors from focusing on the underlying positive dynamics of the business.